Cutia Therapeutics (02487.HK)

Cutia Therapeutics is a holding company, which engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 298 full-time employees. The company went IPO on 2023-06-12. The firm is dedicated to developing solutions in the dermatology treatment and care market, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management. The firm is primarily engaged in the distribution of scalp diseases and care products, as well as certain skin care products. The firm's principal pipeline products include topical finasteride spray CU-40102, topical 4% minocycline foam CU-10201, topical novel small molecule agent CU-10101, localized topical lidocaine and tetracaine cream CU-30101 and recombinant mutant collagenase CU-20401.